Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.4
3.9
Journals
JCM
Special Issues
Cardiovascular Disease in the Era of COVID-19
share announcement

Cardiovascular Disease in the Era of COVID-19

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Cardiology".

Deadline for manuscript submissions: 20 August 2024 | Viewed by 398

Special Issue Editor

Dr. Sophie I. Mavrogeni

E-Mail Website
Guest Editor
Department of Cardiology, Onassis Cardiac Surgery Center, 17674 Athens, Greece
Interests: clinical cardiology; autoimmune diseases; non-ischemic cardiomyopathy; cardiovascular magnetic resonance imaging (CMR)
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

In addition to involving the respiratory system, COVID-19 can also affect the cardiovascular system, causing acute and/or chronic myocardial injuries. COVID-19 patients may present cardiovascular involvement irrespective of the severity of COVID-19 illness. However, patients with known cardiovascular disease (CVD) and COVID-19 illness are likely to develop severe symptoms and are at a greater risk of death. Furthermore, there is no clear algorithm about how to address the adverse cardiac events due to COVID-19, except to treat patients’ symptoms as they appear. Understanding the pathophysiology of CVD due to COVID-19, as well as the underlying mechanisms of myocardial injury, the role of biomarkers/cardiac imaging and the related medical treatment/follow-up strategies is absolutely necessary to improve patient treatment/prognosis. However, there are many issues regarding diagnosis, treatment and the follow-up of these patients.

In this Special Issue of JCM, we intend to present publications regarding the prevalence of CVD, diagnosis using biomarkers/cardiovascular imaging, validation of treatment and the follow-up protocol. In addition, publications regarding the role of vaccination in the development of cardiovascular disease will be also included.

We strongly believe that this Special Issue will clarify questions regarding CVD due to COVID-19, and we invite you to submit your valuable contribution and provide an opportunity to build an exciting and useful issue about CVD in the era of COVID-19.

Dr. Sophie I. Mavrogeni
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cardiovascular disease
  • COVID-19
  • myocardial injuries
  • cardiovascular involvement
  • cardiac imaging

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

12 pages, 918 KiB  
Article
Elevated Troponins after COVID-19 Hospitalization and Long-Term COVID-19 Symptoms: Incidence, Prognosis, and Clinical Outcomes—Results from a Multi-Center International Prospective Registry (HOPE-2)
by Ravi Vazirani, Gisela Feltes, Rafael Sánchez-del Hoyo, María C. Viana-Llamas, Sergio Raposeiras-Roubín, Rodolfo Romero, Emilio Alfonso-Rodríguez, Aitor Uribarri, Francesco Santoro, Víctor Becerra-Muñoz, Martino Pepe, Alex F. Castro-Mejía, Jaime Signes-Costa, Adelina Gonzalez, Francisco Marín, Javier Lopez-País, Enrico Cerrato, Olalla Vázquez-Cancela, Carolina Espejo-Paeres, Álvaro López Masjuan, Lazar Velicki, Ibrahim El-Battrawy, Harish Ramakrishna, Antonio Fernandez-Ortiz and Ivan J. Nuñez-Giladd Show full author list remove Hide full author list
J. Clin. Med. 2024, 13(9), 2596; https://doi.org/10.3390/jcm13092596 (registering DOI) - 28 Apr 2024
Viewed by 137
Abstract
Background: Acute cardiac injury (ACI) after COVID-19 has been linked with unfavorable clinical outcomes, but data on the clinical impact of elevated cardiac troponin on discharge during follow-up are scarce. Our objective is to elucidate the clinical outcome of patients with elevated [...] Read more.
Background: Acute cardiac injury (ACI) after COVID-19 has been linked with unfavorable clinical outcomes, but data on the clinical impact of elevated cardiac troponin on discharge during follow-up are scarce. Our objective is to elucidate the clinical outcome of patients with elevated troponin on discharge after surviving a COVID-19 hospitalization. Methods: We conducted an analysis in the prospective registry HOPE-2 (NCT04778020). Only patients discharged alive were selected for analysis, and all-cause death on follow-up was considered as the primary endpoint. As a secondary endpoint, we established any long-term COVID-19 symptoms. HOPE-2 stopped enrolling patients on 31 December 2021, with 9299 patients hospitalized with COVID-19, of which 1805 were deceased during the acute phase. Finally, 2382 patients alive on discharge underwent propensity score matching by relevant baseline variables in a 1:3 fashion, from 56 centers in 8 countries. Results: Patients with elevated troponin experienced significantly higher all-cause death during follow-up (log-rank = 27.23, p < 0.001), and had a higher chance of experiencing long-term COVID-19 cardiovascular symptoms. Specifically, fatigue and dyspnea (57.7% and 62.8%, with p-values of 0.009 and <0.001, respectively) are among the most common. Conclusions: After surviving the acute phase, patients with elevated troponin on discharge present increased mortality and long-term COVID-19 symptoms over time, which is clinically relevant in follow-up visits. Full article
(This article belongs to the Special Issue Cardiovascular Disease in the Era of COVID-19)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop